Rezurock
| Chemical Name | belumosudil |
| Dosage Form | Tablet (oral; 200mg) |
| Drug Class | Kinase inhibitors |
| System | Multiple |
| Company | Kadmon Pharmaceuticals |
| Approval Year | 2021 |
Indication
- For the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.